Navigation

Obesity - phentermine (with topiramate) [ID543]

Phentermine with topiramate for the treatment of obesity and overweight

Status: Suspended
Expected date of issue: TBC
Referral date: July 2012
Process: STA
Notes:

Scoped as part of batch 23

Topic area:
  • Endocrine, nutritional and metabolic
  • Public health
  • Therapeutic procedures
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Pilar Pinilla-Dominguez
Communications manager: Alice Law
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 14 November 2012
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Vivus (phentermine with topiramate)

Patient/carer groups

  • HEART UK

Professional groups

  • Royal College of Nursing              
  • Royal College of Physicians
  • The Obesity Management Association

Others

  • Arden PCT Cluster
  • Department of Health
  • Welsh Government

General

  • Commissioning Support  Appraisals Services
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare Products Regulatory Agency

Comparator manufacturers

  • GlaxoSmithKline (orlistat) (confidentiality agreement not signed, not participating)
  • Roche Products (Orlistat) (confidentiality agreement not signed, not participating)
  • Teva UK (orlistat) (confidentiality agreement not signed, not participating)

Relevant research groups

  • Cochrane Heart Group

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • School of Health and Related Research Sheffield (ScHARR)  

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
29 April 2013

The Department of Health asked the Institute to conduct an appraisal of phentermine with topiramate for the treatment of obesity and overweight and to provide guidance on its use to the NHS in England and Wales. 

The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently re-examined its initial negative opinion for phentermine and has confirmed the refusal of the marketing authorisation.

NICE has therefore decided to suspend this appraisal indefinitely.

As this topic has been referred to the Institute we will continue to monitor any developments and will update this webpage if the situation changes.

6 November 2012

Following an update on the regulatory status of this technology which has received a negative CHMP opinion, we are suspending the appraisal whilst we consider the next steps.  Consequently the discussion of this appraisal at the Committee meeting on 27 February 2013 has been cancelled.

 

Top


 

Key documents

This page was last updated: 29 April 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.